Background: Methotrexate (MTX) is widely used in the treatment of Rheumatoid arthritis (RA) as first line disease modifying anti-rheumatoid drug. Low dose MTX may reduce lung function status in RA patients. Objective: To observe the changes in large airway ventilatory variables in RA patients after MTX therapy. Methods: For this prospective observational study, 24 female RA patients of age ranges between 15 to 65 years were selected from the Out-Patient Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Age and BMI matched 24 apparently healthy females were also selected Control. To assess the large airway ventilatory function, FVC, FEV 1 , FEV 1 / FVC% and PEFR of all subjects were measured with a portable digital Spirometer, PONY FX (Cosmed, Italy) at Day 0. In addition, all these variables were again measured in the RA patients after 180 days of MTX therapy. For statistical analysis, independent sample t test and paired sample t test were performed. Results: All the study variables (except FEV 1 /FVC%) were significantly (p<0.001) lower in RA groups at day 0 as well as at day 180, compared to healthy controls. Again all these variables were almost similar in the RA patients at day 180 when compared to those of day 0. Conclusion: Large airway ventilatory function deteriorated in RA patients, which may not be recovered by six months methotraxate therapy.
Large airway ventilatory functions in female patients of rheumatoid arthritis with methotrexate therapy-is there any change? Introduction
Received 11 January 2018; Accepted 03 April 2018 heumatoid arthritis (RA) is the most common persistent autoimmune inflammatory connective tissues R disorder throughout the world. Global prevalence of RA is approximately 1% and in Bangladesh is about 1.6% [1] [2] . Typical presentations are joint pain, swelling and stiffness, affecting small joints of hands, feet and wrist associated with systemic disorder and extra-articular features 3 . The etiology of rheumatoid arthritis is unknown but linked with genetic and environmental factors which are implicated in the pathogenesis of the disease.
In RA, pulmonary involvement is the second common extra-articular manifestation and 25% to 70% patients with RA presents with pulmonary abnormalities [4] [5] . About 22% of the affected RA patients died due to respiratory complication ranging from pleurisy, pulmonary nodules, pulmonary vasculitis, interstitial pulmonary fibrosis, airway disease and pleural effusion 6 to fibrosed lung followed by impaired lung function [6] [7] [8] . Forty (40%) percent of the RA patients suffers with interstitial lung disease and subclinical alveolitis [9] [10] [11] . Small airway involvement was found in 38% of RA patients which appears as the commonest form of pulmonary involvement of rheumatoid lung disease 11 . About 85% of RA patients suffer with thickened bronchial wall. Bronchial dilatation is present in 62% patients with RA. Moreover, 14% patients with RA are affected with small airway obstruction [12] [13] [14] .
For the treatment of RA, methotraxate (MTX, N-10 methyl aminopterin, a folate analogue) is an ideal agent, which halts the progression of bony erosions, thereby preventing joint deformity and morbidity. [15] [16] [17] [18] Pulmonary complications occurred in 7.6% RA patients treated with low dose MTX [19] [20] [21] . It is also reported that 1 to 7% patients treated with MTXmight develop pulmonary toxicity within first year of treatment [22] [23] . Approximately 17.5% RA patients treated with MTX those who develop lung disease might die from this complication 22 .
Significantly lower mean percentages of predicted value of FVC in RA patients without [5] [6] [24] [25] and after low dose MTX therapy have been reported [26] [27] . On the other hand, non-significant decrease in FVC value after MTX treatment in patients with RA has also been published [28] [29] .
Similar pattern of change involving FEV 1 was also reported in RA without and after MTX treatent. 8, [25] [26] [27] [28] [29] [30] .
In addition, similar data in FEV 1 /FVC%in RA before and after MTX treatment has been published 25,30-31 but Khadadah et al. 27 reported significant increment in FEV 1 /FVC ratio in MTX treated RA patients compared to baseline. Along with FVC, FEV 1, FEV 1 /FVC%, PEFR (indicator of respiratory muscle strength) was also shown to be lowered in patients of RA 8 .
Because of the inconsistent outcomes of different studies, this study has been designed to investigate the changes of spirometric variables in female RA patients and also to compare these data after six months MTX therapy in same patients.
Methods
This prospective observational study was carried out in the Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from March 2017 to February 2018. The protocol of this study was approved by the Institutional Review Board, BSMMU. For this, 24 female diagnosed RA patients by the rheumatologist (American College of Rheumatology (ACR) 2010 criteria 32 [40] ) of 15 to 65 year were selected from the Out Patient Department (OPD) of Rheumatology, BSMMU. Age and BMI matched 24 apparently healthy females were further selected through personal contact (Control). Subjects with history of smoking, bronchial asthma, COPD, pulmonary fibrosis, pneumonia, tuberculosis, pneumothorax, pneumoconiosis, extrinsic allergic alveolities, ischemic heart disease, hepatic disease, kidney disease, musculoskeletal abnormality, collagen vascular disease (dermatomyositis, psoriatic arthritis, SLE) in addition to current pregnancy or planning to pregnancy orcurrent lactation, were excluded from study. After selection, the objectives, nature, purpose were explained in detail to the subjects and informed written consent was taken from all subjects. Detailed family history, medical history and thorough physical examination of each patient were done and documented. Large airway ventilatory variables (FVC, FEV 1 , FEV 1 /FVC%, PEFR) were measured with a portable digital Spirometer, PONY FX (Cosmed, Italy), at baseline of all subjects (at day 0) and also after completion of six months MTX therapy (at day 180). Data were expressed as mean±SE of percentage of predicted value. For statistical analysis, independent sample t test and paired sample t test were performed by using SPSS(version 20). In the interpretation of results, p value of d 0.05 was considered as statistically significant.
Results
In this study, both the control and RA patients were comparable, in respect of age and BMI, as their differences were statistically non significant (Figure 1) . At base line, the mean percentage predicted values of FVC (Figure 2A ), FEV 1 ( Figure 2B ), PEFR ( Figure 2D ) were significantly (pd"0.001) lower and FEV 1 /FVC% ( Figure 2C ) was significantly (p£0.001) higher in RA patients at Day 0 before MTX therapy, compared to healthy control. In addition, FVC (Figure 2A) , FEV 1 / FVC% ( Figure 2C ), PEFR ( Figure 2D) were slightly increased and FEV 1 ( Figure 2B ) was slightly decreased at day 180 (after six months MTX therapy)in comparison to those of day 0 but the differences were statistically non Data were expressed as mean±SE of percentage of predicted values of forced vital capacity (A), forced expiratory volume in 1 st second (B), FEV1/FVC ratio (C) and peak expiratory flow rate (D).Statistical analysis was done by independent sample t test (a=control vs RA at day 0; b=control vs RA at day 180) and Student's paired t test (c=RA at day 0 vs RA at day 180).***=significant (pd"0.001); ns=non significant; RA=Rheumatoid arthritis; day 0=before methotraxate therapy; day 180=after 6 months of methotraxate therapy 
Discussion
In the present study, we found significantly lowered FVC, FEV 1 and PEFR in RA patients at baseline (before MTX therapy) than those of control group. Similar findings were observed by several investigators 5, 8, 25, 30 . The cause of our finding might be due to movement limitation of chest cage,because of synovial joint affection (specially, costovertebral and costochondral) [33] [34] or respiratory muscle weakness 13, 33-35[43] or inflammatory change in the bronchi 13, 29, [33] [34] in RA. We also found significantly higher FEV 1 / FVC% at baseline in our RA patients than those of healthy control. Similar finding was observed by several investigators 25, 30 . This result suggests restrictive pattern of lung function impairment, which might be due to fibrotic change of lung parenchyma by augmentation of parenchymal inflammation through protein citrullination 29, [36] [37] or differentiation and proliferation of fibroblast in lung parenchyma along with increased activity of matrix metalloproteinase 13, [36] [37] in this morbid disorder.
Again, all of the large airway function variables (FVC, FEV 1 , FEV 1 /FVC%, PEFR) of our RA patients were almost similar after six months of MTX therapy to those of their baseline, as their differences were statistically non-significant. These observations were in agreement with findings of other investigators of different countries 8, 27, 29, 38 . Our findings suggest no effect of MTX on improvement of ventilatory function (in spite of decrement of RA symptoms) of our RA patients, which might be due to decrement of alveolar epithelial cell and increment of myelofibroblasts proliferation by MTX 23, 39 causing altered physiological and mechanical function of lung and subsequently increment of airway resistance 23, 27, 40 .
Conclusion
From our study it is concluded that, large airway ventilatory functions deteriorate in RA patients, which may not be improved with six months' traditional disease modifying anti rheumatoid drug -methotraxate. Study on RA patients with MTX therapy of longer duration is further recommended for inferential outcome.
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